Informação sobre produto
- 1-Propanol, 3-[[2-[(1H-benzimidazol-2-ylthio)methyl]-3-methyl-4-pyridinyl]oxy]-
- 2-[[[4-(3-Hydroxypropoxy)-3-methyl-2-pyridyl]methyl]thio]-1H-benzimidazole
- 3-({2-[(1H-benzimidazol-2-ylsulfanyl)methyl]-3-methylpyridin-4-yl}oxy)propan-1-ol
- 3-[[2-[(1H-Benzimidazol-2-ylthio)methyl]-3-methyl-4-pyridinyl]oxy]-1-propanol
Rabeprazole is a proton pump inhibitor (PPI) that inhibits the secretion of stomach acid. It is a racemic mixture of two enantiomers, desmethyl rabeprazole and thiomethyl rabeprazole. The pharmacokinetics of rabeprazole have been determined in healthy Chinese subjects and in human urine using liquid chromatography-mass spectrometry (LC-MS). These experiments showed that desmethyl rabeprazole has a longer half-life than thiomethyl rabeprazole. In addition, the LC-MS parameters were used to calculate the pharmacokinetic parameters of both enantiomers. Rabeprazole has been shown to inhibit donepezil metabolism, which may result in an increased exposure to donepezil.